EP 3919065 A1 20211208 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES

Title (en)

COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON TYP-1-DIABETES

Title (fr)

COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU DIABÈTE DE TYPE 1

Publication

EP 3919065 A1 20211208 (EN)

Application

EP 21185734 A 20170113

Priority

US 201662278493 P 20160114
US 201662350472 P 20160615
EP 17702950 A 20170113
IB 2017050204 W 20170113

Abstract (en)

Provided herein are compositions and methods for the treatment of type 1 diabetes (T1D) in mammalian subjects. The compositions include lactic acid fermenting bacteria (LAB) expressing an IL-2 gene and a TID-specific self-antigen (e.g., proinsulin (PINS)) gene. Exemplary methods include: orally administering to a mammalian subject, a therapeutically effective amount of the composition. The composition can be administered to the subject mucosally, resulting in delivery of the LAB into the gastrointestinal tract, where the LAB is released. Bioactive polypeptides expressed by the LAB are thus administered via mucosal delivery. The LAB may be selected to deliver a low-dose of IL-2 to the subject. The methods may not require concomitant systemic anti-CD3 antibody treatment. The methods may be suited for subjects possessing residual beta-cell function, e.g., those with recentonset T1D.

IPC 8 full level

A61K 35/744 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61P 3/10 (2006.01); A61P 37/06 (2006.01); C12N 1/00 (2006.01); C12N 1/20 (2006.01); C12N 15/09 (2006.01); C12R 1/01 (2006.01)

CPC (source: EP RU US)

A61K 35/744 (2013.01 - EP RU US); A61K 35/745 (2013.01 - US); A61K 35/747 (2013.01 - RU US); A61K 38/2013 (2013.01 - EP RU); A61K 38/28 (2013.01 - EP RU); A61K 39/0008 (2013.01 - EP); A61K 39/3955 (2013.01 - US); A61P 3/10 (2018.01 - EP RU); C07K 14/55 (2013.01 - EP); C12N 1/20 (2013.01 - RU); A61K 2039/523 (2013.01 - EP US); A61K 2039/542 (2013.01 - EP US); A61K 2039/545 (2013.01 - EP US); A61K 2039/55533 (2013.01 - EP US)

Citation (applicant)

US 2014105863 A1 20140417 - VANDEN-BROUCKE KLAAS [BE], et al
WO 02090551 A2 20021114 - VLAAMS INTERUNIV INST BIOTECH [BE], et al
GB 2278358 B 19950726 - LYNXVALE LTD [GB]
NL 9500135 W 19950411
WO 9632487 A1 19961017 - TNO [NL], et al
WO 9317117 A1 19930902 - LYNXVALE LTD [GB]
US 8759088 B2 20140624 - STEIDLER LOTHAR [BE], et al
US 4518584 A 19850521 - MARK DAVID F [US], et al
US 81065685 A 19851217
EP 0091539 A1 19831019 - AJINOMOTO KK [JP], et al
EP 0088195 A2 19830914 - TAKEDA CHEMICAL INDUSTRIES LTD [JP]
US 2012244112 A1 20120927 - AST OLIVER [CH], et al
US 7569215 B2 20090804 - WITTRUP K DANE [US], et al
US 5229109 A 19930720 - GRIMM ELIZABETH A [US], et al
US 2006269515 A1 20061130 - DENIS-MIZE KIMBERLY [US], et al
EP 1730184 A2 20061213 - CHIRON CORP [US]
WO 2005086751 A2 20050922 - CHIRON CORP [US], et al
US 5972685 A 19991026 - BEITZ DONALD C [US], et al
WO 0018377 A1 20000406 - WARNER LAMBERT CO [US], et al
WO 0022909 A2 20000427 - BIOTECH AUSTRALIA PTY LTD [AU]
US 2012039853 A1 20120216 - CORVELEYN SAM [BE], et al
US 6387352 B1 20020514 - JOHANSEN ERLING [US], et al
US 6348187 B1 20020219 - PAN PAULINE [US], et al
US 6171611 B1 20010109 - PICCIANO DANTE J [US]
US 6165494 A 20001226 - PICCIANO DANTE J [US]
US 6117417 A 20000912 - WICKS MARK ANDREW [GB], et al
US 5993785 A 19991130 - JOHANSEN ERLING [US], et al
US 5695746 A 19971209 - GARLICK JR THEODORE HARRISON [US], et al
US 5470561 A 19951128 - KLUGKIST JAN [GB], et al
US 4919918 A 19900424 - COLE B HARRISON [US], et al
US 2004076590 A1 20040422 - WILKINS JOE S [US]
US 2003152530 A1 20030814 - JOHANSEN ERLING [US], et al
US 2002044910 A1 20020418 - JOHANSEN ERLING [US], et al
US 5700782 A 19971223 - COPE FREDERICK OLIVER [US], et al
US 5869118 A 19990209 - MORRIS JEFFREY G [US], et al
US 5223285 A 19930629 - DEMICHELE STEPHEN J [US], et al
VAN BELLE, T.L. ET AL., PHYSIOL. REV., vol. 91, no. 1, 2011, pages 79 - 118
YU, A. ET AL., DIABETES, vol. 64, 2015, pages 2172 - 2183
HARTEMANN A. ET AL., LANCET DIABETES ENDOCRINOL., vol. 1, 2013, pages 295 - 305
ROSENZWAJG M. ET AL., JAUTOIMMUN., vol. 58, 2015, pages 48 - 58
STEIDLER, L. ET AL., NAT. BIOTECHNOL., vol. 21, no. 7, 2003, pages 785 - 789
ROBERT S.STEIDLER L., MICROB. CELL FACT., 2014, pages l 1
ROBERT, S. ET AL., DIABETES, vol. 63, 2014, pages 2876 - 2887
TAKIISHI, T. ET AL., J. CLIN. INV., vol. 122, no. 5, 2012, pages 1717 - 1725
JONES A.GHATTERSLEY A.T., DIABETIC MEDICINE, vol. 30, 2013, pages 803 - 817
LITTLE RR ET AL., CLIN. CHEM., vol. 54, 2008, pages 1023 - 1026
WIEDMEYER ET AL., CLIN. CHEM., vol. 53, 2007, pages 784 - 787
DEMEESTER ET AL., DIABETES CARE, vol. 38, no. 4, 2015, pages 644 - 651
STROBEL ET AL., IMMUNOLOGY, vol. 49, 1983, pages 451 - 456
MAYERSHAO, NATURE REV. IMMUNOL., vol. 4, 2004, pages 407 - 419
GASSON, M.J., J. BACTERID., vol. 154, 1983, pages 1 - 9
SORENSEN ET AL., APPL. ENVIRON. MICROBIOL., vol. 66, 2000, pages 1253 - 1258
ARGOS, EMBO J., vol. 8, 1989, pages 779 - 785
CHIEN: "Short Protocols in Molecular Biology", 1992, JOHN WILEY & SONS
WATERFIELD NR ET AL., GENE, vol. 165, no. 1, 1995, pages 9 - 15
RAPOPORT, CURRENT OPINION IN BIOTECHNOLOGY, vol. 1, 1990, pages 21 - 27
HARWOODCUTTING: "PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS", 1990, WILLIAM AND WILKINS
VAN ASSELDONK ET AL., MOL. GEN. GENET., vol. 240, 1993, pages 428 - 434
DAYHOFF, THE ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, vol. 5, 1978
TANIGUCHI ET AL., NATURE, vol. 302, no. 5906, 1983, pages 305 - 10
DEVOS ET AL., NUCLEIC ACIDS RES., vol. 11, no. 13, 1983, pages 4307 - 23
STEIDLER ET AL., SCIENCE, vol. 289, no. 5483, 2000, pages 1352 - 1355
HARTEMANN ET AL., LANCET DIABETES ENDOCRINOL, vol. 1, no. 4, 2013, pages 295 - 305
ROBERT ET AL., BENEF. MICROBES, vol. 6, no. 4, 2015, pages 591 - 601
"NCBI", Database accession no. NM_006262.3
ARDEN ET AL., DIABETES, vol. 48, no. 3, 1999, pages 531 - 542
MARTIN ET AL., J. BIOL. CHEM., vol. 276, no. 27, 2001, pages 25197 - 207
DOGRA ET AL., DIABETOLOGIA, vol. 49, no. 5, 2006, pages 953 - 7
PRESCOTT ET AL.: "NOVEL DRUG DELIVERY", 1989, J. WILEY & SONS
CAZZANIGA ET AL., INT. J. PHARM., vol. 108, no. 1, 1994, pages 77 - 83
BRUSCHI M. L.DE FREITAS O., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 31, 2005, pages 293 - 310
BATCHELOR ET AL., INT. J. PHARM., vol. 238, 2002, pages 123 - 32
GASSON MJ, J. BACTERIOL., vol. 154, no. 1, 1983, pages 1 - 9
SANDERS ET AL., J. BACTERIOL., vol. 177, no. 18, 1995, pages 5254 - 5260
SCHOTTE ET AL., ENZYME MICROB. TECHNOL., vol. 27, no. 10, 2000, pages 761 - 765
DROUAULT S ET AL., APPL. ENVIRON. MICROBIOL., vol. 65, no. 11, 1999, pages 4881 - 6
GAGLIANI, N. ET AL., NAT. MED., vol. 19, no. 6, 2013, pages 739 - 746
ANTONIOLI, L. ET AL., TRENDS MOL. MED., vol. 19, no. 6, 2013, pages 355 - 367
TAKIISHI, T. ET AL., J CLIN.INVEST., vol. 122, no. 5, 2012, pages 1717 - 1725
"GenBank", Database accession no. HM585371.1
SUAREZ-PINZON WL ET AL.: "Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice", DIABETES, vol. 57, 2008, pages 3281 - 8
TANG QBLUESTONE JA., NAT. IMMUNOL., vol. 9, no. 3, 2008, pages 239 - 244
ZHENG YRUDENSKY AY, NAT. IMMUNOL., vol. 8, no. 5, 2007, pages 457 - 462
GRINBERG-BLEYER Y. ET AL., J. EXP. MED., vol. 207, no. 9, 2010, pages 1871 - 1878

Citation (search report)

[Y] WO 2013036914 A1 20130314 - UNIV FLORIDA [US], et al
[Y] US 2014004080 A1 20140102 - KLATZMANN DAVID [FR], et al
[YD] TATIANA TAKIISHI ET AL: "Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 5, 1 May 2012 (2012-05-01), US, pages 1717 - 1725, XP055308282, ISSN: 0021-9738, DOI: 10.1172/JCI60530
[Y] S. ROBERT ET AL: "Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice", DIABETES, vol. 63, no. 8, 27 March 2014 (2014-03-27), US, pages 2876 - 2887, XP055351010, ISSN: 0012-1797, DOI: 10.2337/db13-1236
[Y] R. MALLONE ET AL: "Of Bugs and Men: Antigen-Fortified Lactoccoccus lactis for Type 1 Diabetes Immunotherapy", DIABETES, vol. 63, no. 8, 24 July 2014 (2014-07-24), US, pages 2603 - 2605, XP055350900, ISSN: 0012-1797, DOI: 10.2337/db14-0587
[Y] AIXIN YU ET AL: "Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes", DIABETES, vol. 64, no. 6, 9 January 2015 (2015-01-09), US, pages 2172 - 2183, XP055350944, ISSN: 0012-1797, DOI: 10.2337/db14-1322
[Y] ROSENZWAJG MICHELLE ET AL: "Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients", JOURNAL OF AUTOIMMUNITY, vol. 58, 26 January 2015 (2015-01-26), pages 48 - 58, XP029204247, ISSN: 0896-8411, DOI: 10.1016/J.JAUT.2015.01.001

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2017122180 A1 20170720; AU 2017208153 A1 20180809; AU 2017208153 B2 20210128; AU 2021202600 A1 20210527; AU 2021202600 B2 20231102; CA 3011331 A1 20170720; CN 108883140 A 20181123; DK 3402499 T3 20210927; EP 3402499 A1 20181121; EP 3402499 B1 20210721; EP 3919065 A1 20211208; EP 3919065 A9 20230802; EP 3919065 B1 20231108; EP 3919065 B9 20240124; JP 2019505524 A 20190228; JP 2022023025 A 20220207; JP 2023166421 A 20231121; JP 7292877 B2 20230619; RU 2018126399 A 20200214; RU 2018126399 A3 20200609; RU 2760997 C2 20211202; US 10905727 B2 20210202; US 11786567 B2 20231017; US 2019022154 A1 20190124; US 2021154247 A1 20210527; US 2024082323 A1 20240314

DOCDB simple family (application)

IB 2017050204 W 20170113; AU 2017208153 A 20170113; AU 2021202600 A 20210427; CA 3011331 A 20170113; CN 201780011344 A 20170113; DK 17702950 T 20170113; EP 17702950 A 20170113; EP 21185734 A 20170113; JP 2018536741 A 20170113; JP 2021139503 A 20210830; JP 2023133189 A 20230818; RU 2018126399 A 20170113; US 201716069947 A 20170113; US 202117150352 A 20210115; US 202318463461 A 20230908